Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505240 | 0.87 | NPC1 (0.46) | NPC1KDM4EEGLN2 | |
| SCHEMBL6494387 | 0.87 | NPC1 (0.49) | NPC1KDM4ECRHR1EGLN2MAPT | |
| SCHEMBL6504484 | 0.87 | NPC1 (0.43) | NPC1KDM4EEGLN2 | |
| SCHEMBL6497176 | 0.86 | NPC1 (0.46) | NPC1KDM4ECRHR1EGLN2MAPT | |
| SCHEMBL6504656 | 0.85 | NPC1 (0.43) | NPC1KDM4ECRHR1MAPT | |
| SCHEMBL6506300 | 0.85 | NPC1 (0.47) | NPC1KDM4EEGLN2 | |
| SCHEMBL6505513 | 0.84 | NPC1 (0.51) | NPC1KDM4ECRHR1EGLN2MAPT | |
| SCHEMBL6505585 | 0.83 | NPC1 (0.46) | NPC1KDM4EEGLN2 | |
| SCHEMBL6495917 | 0.83 | NPC1 (0.49) | NPC1KDM4ECRHR1EGLN2MAPT | |
| SCHEMBL6504003 | 0.83 | NPC1 (0.45) | NPC1KDM4ECRHR1EGLN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958341-B2 | Pyrazolopyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | claimed |
| US-6958341-B2 | Pyrazolopyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | WILDE RICHARD G (US) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | CRHR1, CRHR2, CRH | NPC1 1126/4885KDM4E 4339/4885CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.